Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences
KA Stock | 0.48 0.04 7.69% |
About 51% of Kineta's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Kineta Inc suggests that some traders are interested. The current market sentiment, together with Kineta's historical and current headlines, can help investors time the market. In addition, many technical investors use Kineta Inc stock news signals to limit their universe of possible portfolio assets.
Kineta |
TuHURA has an exclusive right to negotiate to acquire Kinetas KVA12123 Immuno-Oncology Drug Program Kineta will receive a 5 million Nonrefundable Payment from TuHURA KVA12123 is currently in a Phase 1Phase 2 Clinical Study in the United States SEATTLE, July 08, 2024 -- Kineta, Inc. , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into
Read at finance.yahoo.com
Kineta Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Kineta can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Kineta Fundamental Analysis
We analyze Kineta's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kineta using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kineta based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Kineta is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Kineta Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kineta stock to make a market-neutral strategy. Peer analysis of Kineta could also be used in its relative valuation, which is a method of valuing Kineta by comparing valuation metrics with similar companies.
Peers
Kineta Related Equities
PHVS | Pharvaris | 2.23 | ||||
MLYS | Mineralys Therapeutics, | 1.76 | ||||
ANEB | Anebulo Pharmaceuticals | 0.72 | ||||
DYAI | Dyadic International | 0.62 | ||||
FBRX | Forte Biosciences | 0.52 | ||||
XOMAO | XOMA | 0.51 | ||||
LUMO | Lumos Pharma | 0.23 | ||||
RZLT | Rezolute | 0.22 | ||||
INKT | Mink Therapeutics | 0.16 | ||||
PEPG | PepGen | 0.00 | ||||
ALVR | Allovir | 0 | ||||
TPST | Tempest Therapeutics | 0.93 | ||||
PTIX | Protagenic Therapeutics | 1.00 | ||||
MOLN | Molecular Partners | 2.16 | ||||
CADL | Candel Therapeutics | 2.81 | ||||
ANTX | AN2 Therapeutics | 3.38 | ||||
DMAC | DiaMedica Therapeutics | 4.61 | ||||
SILO | Silo Pharma | 8.70 |
Complementary Tools for Kineta Stock analysis
When running Kineta's price analysis, check to measure Kineta's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kineta is operating at the current time. Most of Kineta's value examination focuses on studying past and present price action to predict the probability of Kineta's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kineta's price. Additionally, you may evaluate how the addition of Kineta to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |